What the study found
The review finds that pregnancy in familial hypercholesterolemia, a genetic condition causing very high cholesterol, requires careful balancing of maternal atherosclerotic cardiovascular disease risk and fetal safety. It reports that heterozygous familial hypercholesterolemia does not appear to significantly increase fetal adverse outcomes, while homozygous familial hypercholesterolemia is associated with substantially higher maternal morbidity.
Why the authors say this matters
The authors conclude that pregnancy in familial hypercholesterolemia needs a nuanced, stage-specific, individualized approach. They also say that expanding pregnancy registries and prospective studies is essential to guide evidence-based care and refine future recommendations.
What the researchers tested
This is a review that synthesizes current evidence, research gaps, and emerging data on lipid-lowering strategies and guideline recommendations for pregnancy in familial hypercholesterolemia. It draws on registries, observational studies, and evolving guidance.
What worked and what didn't
Registry and observational data indicate that heterozygous familial hypercholesterolemia does not significantly increase congenital malformation, prematurity, or low birth weight, although there may be a predisposition to early atherogenesis. The review also notes maternal risks such as preeclampsia, endothelial dysfunction, and a prothrombotic tendency, and it states that homozygous familial hypercholesterolemia carries substantially higher morbidity.
What to keep in mind
The abstract does not describe detailed study limitations beyond noting research gaps. It also states that statins remain contraindicated in most guidelines during pregnancy and lactation, despite emerging evidence of a lack of major teratogenic risk, and that time off statins is a critical gap in atherosclerotic cardiovascular disease prevention.
Key points
- Pregnancy in familial hypercholesterolemia requires balancing maternal cardiovascular risk with fetal safety.
- Heterozygous familial hypercholesterolemia does not appear to significantly increase major fetal adverse outcomes in available registry and observational data.
- Homozygous familial hypercholesterolemia is associated with substantially higher maternal morbidity.
- Suggested management includes dietary optimization, selective low-dose statin use in high-risk homozygous cases, and LDL apheresis for severe cases.
- Most guidelines still contraindicate statins during pregnancy and lactation.
- The authors say more pregnancy registries and prospective studies are needed.
Disclosure
- Research title:
- Pregnancy in familial hypercholesterolemia needs individualized care
- Authors:
- Jayanthi Ramanathan, D. Sullivan, Gerald Watts, Kirsten B. Holven, Yee Sian Tiong
- Institutions:
- Ng Teng Fong General Hospital, Royal Perth Hospital, Royal Prince Alfred Hospital, Royal Prince Alfred Hospital, University of Oslo
- Publication date:
- 2026-02-05
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with scholarly research without reading academic papers — one filtered digest, every Friday.